



Press Release

CardioComm Solutions, Inc. Receives Notice of Legal Action--Believes Claims are without Merit

Victoria, B.C., October 24, 2008 – CardioComm Solutions, Inc. (TSX-V: EKG) (“CardioComm” or the “Company”) today announced that it has received notice that Strategic Healthcare Sales and Marketing Development LLC (“SHSMD”) has commenced a legal action against the Company in the Ontario Superior Court of Justice. SHSMD seeks monetary damages for CardioComm’s alleged breach of a sales, marketing and business development agreement between the companies dated December 5, 2007.

CardioComm believes that SHSMD’s claims are without merit and intends to vigorously defend the action and to seek costs against SHSMD in addition to such other remedies which may be available to it, including without limitation pursuing a counterclaim against SHSMD for non-performance by SHSMD under the same sales, marketing and business development agreement.

About CardioComm Solutions, Inc.

CardioComm’s patented and proprietary technology is used in products for the recording, viewing, analyzing and storing of electrocardiograms (EKGs), for diagnosis and management of cardiac patients. The Company's products are sold worldwide through a combination of its external distribution network and its North American based sales team. CardioComm has achieved its technical goals of improved access and communication through the development of a real-time EKG viewer. CardioComm is the first company to provide a real-time means of viewing EKGs over a network (LAN, WAN or Internet). This tool enables EKGs to be viewed and controlled live, by physicians, over a global virtual healthcare network. This technology is marketed as Global EKG Management System (GEMST[™]) and GlobalCardio[™]. CardioComm's software products have been cleared for sale in the United States by the U.S. Food and Drug Administration. The Company has earned the latest ISO 13485 certification.

On behalf of the Board of Directors of CardioComm Solutions, Inc.

“Anatoly Langer”

Dr. Anatoly Langer, Chairman

For investor information, please contact:

Ian Klassen
1-604-899-0106

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release